XOMA Corp
NASDAQ: XOMA
$30.07
+$0.05 (+0.2%)
Closing Price on November 21, 2024
XOMA Stock Chart and Intraday Price
XOMA Stock Data
| Asset Type | Stock |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | LIFE SCIENCES |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Address | 2200 POWELL STREET, SUITE 310, EMERYVILLE, CA, US |
| Fiscal Year End | December |
| Latest Quarter | 9/30/2023 |
| Market Cap | 286.05M USD |
| Shares Outstanding | 11,487,800 |
XOMA Articles
Oasis Petroleum, Stem, Tata Motors, Tesla, Textron and Two Harbors Investment were among Tuesday afternoon's analyst upgrades and downgrades.
Published:
The top analyst upgrades, downgrades and other research calls from Tuesday include Biogen, Carbonite, Celgene, Emerson Electric, Kinder Morgan, Netflix and UnitedHealth.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Chesapeake Energy, Lululemon Athletica, Oracle, US Steel, Walt Disney and YogaWorks.
Published:
Last Updated:
24/7 Wall St. has collected several catalysts that are coming up on the calendar in the month of December.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday morning include Ciena, CME Group, Energy Transfer, NVIDIA and U.S. Steel.
Published:
Last Updated:
Last week, a few biotech companies made absolutely massive runs, while others had serious falls.
Published:
Last Updated:
One thing all biotech investors know is that if a binary event like clinical data goes wrong on a company relying on one specific product, then the end may not be that far behind.
Published:
Thursday's top analyst upgrades, downgrades and initiations include Boeing, EMC, Hertz, Qualcomm, SanDisk, Twitter and XOMA.
Published:
XOMA Corp. (NASDAQ: XOMA) stumbled in trading Wednesday morning, perhaps fell off a cliff might be more accurate.
Published:
Recently, biotech stocks have been getting stung pretty good, and now may be a good time to look at companies with pending catalysts.
Published:
A new report from RBC focuses on top small-cap biotech stocks with key data readouts coming in 2015. Binary events are often the key element in moving a biotech stock higher.
Published:
The steep sell-off at the start of the week certainly enticed some insiders to step up to the plate and add to their positions.
Published:
With the 2014 trading year coming to an end last week, the pace of inside selling picked up a bit as insiders continued to sell stock in time to put it on the 2014 ledger and tax forms.
Published:
In a week when the markets were putting in some all-time highs, many insiders stayed on the sidelines, which is yet another positive as the bull market looks to continue as we head into 2015.
Published:
Insider selling still lags the buyers in overall dollar amount and shares traded. It is possible that many insiders with planned selling programs have already taken some chips off the table.
Published: